EP4157453A4 - METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MYOPIA WITH LEVOCABASTIN, A SELECTIVE HISTAMINE H1 RECEPTOR ANTAGONIST AND DERIVATIVES THEREOF - Google Patents

METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MYOPIA WITH LEVOCABASTIN, A SELECTIVE HISTAMINE H1 RECEPTOR ANTAGONIST AND DERIVATIVES THEREOF Download PDF

Info

Publication number
EP4157453A4
EP4157453A4 EP21816939.9A EP21816939A EP4157453A4 EP 4157453 A4 EP4157453 A4 EP 4157453A4 EP 21816939 A EP21816939 A EP 21816939A EP 4157453 A4 EP4157453 A4 EP 4157453A4
Authority
EP
European Patent Office
Prior art keywords
levocabastin
myopia
prevention
derivatives
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP21816939.9A
Other languages
German (de)
French (fr)
Other versions
EP4157453A1 (en
Inventor
Andrei V. Tkatchenko
Tatiana V. TKATCHENKO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Original Assignee
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University in the City of New York filed Critical Columbia University in the City of New York
Publication of EP4157453A1 publication Critical patent/EP4157453A1/en
Publication of EP4157453A4 publication Critical patent/EP4157453A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EP21816939.9A 2020-06-02 2021-06-02 METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MYOPIA WITH LEVOCABASTIN, A SELECTIVE HISTAMINE H1 RECEPTOR ANTAGONIST AND DERIVATIVES THEREOF Withdrawn EP4157453A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063033291P 2020-06-02 2020-06-02
PCT/US2021/035344 WO2021247635A1 (en) 2020-06-02 2021-06-02 Methods and compositions for preventing and treating myopia with levocabastine, a selective histamine h1-receptor antagonist, and derivatives thereof

Publications (2)

Publication Number Publication Date
EP4157453A1 EP4157453A1 (en) 2023-04-05
EP4157453A4 true EP4157453A4 (en) 2024-06-19

Family

ID=78829881

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21816939.9A Withdrawn EP4157453A4 (en) 2020-06-02 2021-06-02 METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MYOPIA WITH LEVOCABASTIN, A SELECTIVE HISTAMINE H1 RECEPTOR ANTAGONIST AND DERIVATIVES THEREOF

Country Status (7)

Country Link
EP (1) EP4157453A4 (en)
JP (1) JP2023529374A (en)
KR (1) KR20230051130A (en)
CN (1) CN115835905A (en)
CA (1) CA3181292A1 (en)
IL (1) IL298796A (en)
WO (1) WO2021247635A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116270442B (en) * 2021-12-21 2025-07-01 浙江瑞瞳生物科技有限公司 An ophthalmic preparation for correcting near vision

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017140846A1 (en) * 2016-02-19 2017-08-24 D'ambrosio Enzo Maria Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human
WO2019104191A1 (en) * 2017-11-21 2019-05-31 Sydnexis, Inc. Ophthalmic composition and delivery device thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2399555B1 (en) * 2009-02-20 2016-12-07 Seed Co., Ltd. Sustainedly drug-releasing hydrogel contact lens, and drug releasing method using sustainedly drug-releasing hydrogel contact lens
US9827250B2 (en) * 2012-07-31 2017-11-28 Johnson & Johnson Vision Care, Inc. Lens incorporating myopia control optics and muscarinic agents
US10945980B2 (en) * 2016-06-21 2021-03-16 The University Of Newcastle Treatment for myopia
PH12019501945B1 (en) * 2017-02-21 2024-02-21 Singapore Health Serv Pte Ltd Composition and method for preventing or delaying onset of myopia comprising atropine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017140846A1 (en) * 2016-02-19 2017-08-24 D'ambrosio Enzo Maria Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human
WO2019104191A1 (en) * 2017-11-21 2019-05-31 Sydnexis, Inc. Ophthalmic composition and delivery device thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2021247635A1 *

Also Published As

Publication number Publication date
CA3181292A1 (en) 2021-12-09
CN115835905A (en) 2023-03-21
EP4157453A1 (en) 2023-04-05
KR20230051130A (en) 2023-04-17
JP2023529374A (en) 2023-07-10
WO2021247635A1 (en) 2021-12-09
IL298796A (en) 2023-02-01

Similar Documents

Publication Publication Date Title
MA42410B1 (en) Oxysterols and their methods of use
MA45598B1 (en) 24-hydroxy steroles substituted in position 11 for the treatment of diseases linked to the nmda receptor
EP3423047A4 (en) COMPOSITIONS OF SELECTIVE CB2 RECEPTOR AGONISTS FOR THE TREATMENT OF MENTAL DISORDERS
MA39554A3 (en) Spirocycloheptanes used as rock inhibitors
MA53126B1 (en) Selective Estrogen Receptor Degraders
MA42145B1 (en) Apj receptor agonist triazoles
MA34655B1 (en) AMINOALCOOL-SUBSTITUTED 2,3-DIHYDROIMIDAZO [1,2-C] QUINAZOLEIN DERIVATIVES USEFUL IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS AND ANGIOGENESIS RELATED DISEASES
MA55560A (en) N-HETEROAROMATIC AMIDE DERIVATIVES FOR THE TREATMENT OF CANCER
MA54395A (en) CRF1 RECEPTOR ANTAGONIST, PHARMACEUTICAL FORMULATIONS AND CORRESPONDING SOLID FORM FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA
AR068512A1 (en) DERIVATIVES OF 4-ARIL-1H-PIRIDIN-2-DISPOSED WAVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USES OF THE SAME TO TREAT OR PREVENT DISORDERS OF THE CENTRAL NERVOUS SYSTEM
WO2005072308A3 (en) Cgrp receptor antagonists
SA520412443B1 (en) Ophthalmic Compositions Once Daily Administration from Benzimidazole Compounds
MA41238A (en) DERIVATIVES 5 - [(PIPERAZIN-1-YL) -3-OXO-PROPYL] -IMIDAZOLIDINE-2,4-DIONE AS ADAMT INHIBITORS FOR THE TREATMENT OF OSTEOARTHRIT
MA46229B1 (en) Heteroaryl carboxamide compounds as inhibitors of ripk2
MX2024008100A (en) Novel functionalized lactams as modulators of the 5-hydroxytryptamine receptor 7 and their method of use.
MA41633B1 (en) Amide Compounds as 5-HT4 Receptor Agonists
EP3668514A4 (en) SOLID PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF ENDOMETRIOSIS, UTERINE FIBROMAS, POLYCYSTIC OVARY SYNDROME AND ADENOMYOSIS
EP4157453A4 (en) METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MYOPIA WITH LEVOCABASTIN, A SELECTIVE HISTAMINE H1 RECEPTOR ANTAGONIST AND DERIVATIVES THEREOF
EP4192471A4 (en) AGENT FOR TREATING MYOPIA, PREVENTING MYOPIA AND/OR HARRING THE PROGRESSION OF MYOPIA
EP4164640A4 (en) METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING MYOPIA WITH BERBERINE, A BERBERIDACEOUS ALKALOID, AND DERIVATIVES THEREOF
EP3900714A4 (en) AGENT CONTAINING 4-PHENYLBUTYRATE, FOR THE PREVENTION OR TREATMENT OF PRESBYOPIA
EP2215070A4 (en) NOVEL 1,3-DIHYDRO-5-ISOBENZOFURANCARBONITRILE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME FOR THE TREATMENT OF EARLY EJACULATION
EP3730144A4 (en) AGENT FOR THE TREATMENT OF A DISEASE OF THE NERVOUS SYSTEM
MA43913A (en) POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC M1 RECEPTOR
FR2900053B1 (en) USE OF SAFRANAL, CROCINE, PICROCROCIN AND THEIR DERIVATIVES AS A SATITY AGENT FOR THE TREATMENT OF WEST OVERLOAD

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221223

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230606

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61P0027020000

Ipc: A61K0031451000

A4 Supplementary search report drawn up and despatched

Effective date: 20240516

RIC1 Information provided on ipc code assigned before grant

Ipc: C07C 255/60 20060101ALI20240511BHEP

Ipc: A61K 9/06 20060101ALI20240511BHEP

Ipc: A61K 31/19 20060101ALI20240511BHEP

Ipc: A61K 31/445 20060101ALI20240511BHEP

Ipc: A61P 27/10 20060101ALI20240511BHEP

Ipc: A61P 27/02 20060101ALI20240511BHEP

Ipc: A61K 9/00 20060101ALI20240511BHEP

Ipc: A61K 31/451 20060101AFI20240511BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20241206